Abstract:Background: Administration of potent anti-receptor-binding domain (RBD) monoclonal antibodies has been shown to curtail viral shedding and reduce hospitalization in patients with SARS-CoV-2 infection. However, the structure-function analysis of potent human anti-RBD monoclonal antibodies and its links to the formulation of antibody cocktails remains largely elusive. Methods: Previously, we isolated a panel of neutralizing anti-RBD monoclonal antibodies from convalescent patients and showed their neutralization efficacy in vitro. Here, we elucidate the mechanism of action of antibodies and dissect antibodies at the epitope level, which leads to a formation of a potent antibody cocktail. Results: We found that representative antibodies which target non-overlapping epitopes are effective against wild type virus and recently emerging variants of concern, whilst being encoded by antibody genes with few somatic mutations. Neutralization is associated with the inhibition of binding of viral RBD to ACE2 and possibly of the subsequent fusion process. Structural analysis of representative antibodies, by cryo-electron microscopy and crystallography, reveals that they have some unique aspects that are of potential value while sharing some features in common with previously reported neutralizing monoclonal antibodies. For instance, one has a common VH 3-53 public variable region yet is unusually resilient to mutation at residue 501 of the RBD. We evaluate the in vivo efficacy of an antibody cocktail consisting of two potent non-competing anti-RBD antibodies in a Syrian hamster model. We demonstrate that the cocktail prevents weight loss, reduces lung viral load and attenuates pulmonary inflammation in hamsters in both prophylactic and therapeutic settings. Although neutralization of one of these antibodies is abrogated by the mutations of variant B.1.351, it is also possible to produce a bi-valent cocktail of antibodies both of which are resilient to variants B.1.1.7, B.1.351 and B.1.617.2. Conclusions: These findings support the up-to-date and rational design of an anti-RBD antibody cocktail as a therapeutic candidate against COVID-19.

Structure-based development of human antibody cocktails against SARS-CoV-2

Rational development of a human antibody cocktail that deploys multiple functions to confer Pan-SARS-CoVs protection

Structure-guided antibody cocktail for prevention and treatment of COVID-19

Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections

Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2

Structural basis of a two-antibody cocktail exhibiting highly potent and broadly neutralizing activities against SARS-CoV-2 variants including diverse Omicron sublineages

Structure Based Affinity Maturation and Characterizing of SARS-CoV Antibody CR3022 Against SARS-CoV-2 by Computational and Experimental Approaches.

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail

Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes

Antibody Cocktail Exhibits Broad Neutralization Activity Against SARS-CoV-2 and SARS-CoV-2 Variants

Identification of Human Single-Domain Antibodies Against SARS-CoV-2.

hACE2 Fc-neutralization antibody cocktail provides synergistic protection against SARS-CoV-2 and its spike RBD variants

Fully Human Single-Domain Antibodies Against SARS-CoV-2

Long-term passaging of pseudo-typed SARS-CoV-2 reveals the breadth of monoclonal and bispecific antibody cocktails

Structure-guided Affinity Maturation of a Novel Human Antibody Targeting the SARS-CoV-2 Nucleocapsid Protein

Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody

Long-term Passaging of Replication Competent Pseudo-Typed SARS-CoV-2 Reveals the Antiviral Breadth of Monoclonal and Bispecific Antibody Cocktails

Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants

A Cocktail Containing Two Synergetic Antibodies Broadly Neutralizes SARS-CoV-2 and Its Variants Including Omicron BA.1 and BA.2

Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms